Addressing the Critical Need for Novel PTSD Treatments

Post-Traumatic Stress Disorder (PTSD) remains a significant unmet medical need, affecting millions worldwide with debilitating symptoms that impair daily functioning and quality of life. While existing treatments provide relief for some, many patients struggle with persistent anxious arousal—one of the most distressing and treatment-resistant symptoms of PTSD. The need for novel, evidence-based therapies that offer both efficacy and safety is more urgent than ever. Unlike emerging psychedelic-based treatments, which face challenges around safety, regulation, and broad patient acceptability, there is a clear demand for innovative therapies grounded in rigorous science and proven pharmacological mechanisms.

Neuritek Therapeutics is advancing a next-generation approach to PTSD treatment through the development of a first-in-class FAAH inhibitor—a promising drug candidate designed to reduce anxious arousal by modulating key GPCRs (G protein-coupled receptors) involved in stress regulation. This targeted mechanism has shown potential to address hyperarousal symptoms without the psychoactive side effects or regulatory hurdles of psychedelics. With a strong focus on safety, tolerability, and clinical validation, Neuritek aims to deliver a transformative treatment option that can meet the critical needs of patients who currently lack effective solutions.